Clinical Trial

Hizentra® in Inflammatory Neuropathies - pHeNIx Study

Study acronym: pHeNIx
Recruiting
View on ClinicalTrials.gov →
Summary
The pHeNIx study, a national multicentre prospective non-interventional study, should help to describe the conditions of use for Hizentra® and the methods for switching from the IV to SC route in everyday practice, together with the tolerability and efficacy of treatment, which is monitored using a patient application (PRO: Patient-Reported Outcomes).
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2020-12-11; most recent amendment 2025-01-06.
Status change: Suspended → Recruiting 2022-05-06
Status change: Not Yet Recruiting → Suspended 2021-07-02
Trial Details
NCT Number NCT04672733
Lead Sponsor CSL Behring
Conditions Chronic Inflammatory Demyelinating Polyneuropathy
Enrollment 100 participants
Start Date 2022-06-10
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-01-07